Literature DB >> 18842718

Inability of human immunodeficiency virus type 1 produced in murine cells to selectively incorporate primer formula.

Min Wei1, Yiliang Yang, Meijuan Niu, Laurie Desfosse, Robert Kennedy, Karin Musier-Forsyth, Lawrence Kleiman.   

Abstract

Attempts to use the mouse as a model system for studying AIDS are stymied by the multiple blocks to human immunodeficiency virus type 1 (HIV-1) replication that exist in mouse cells at the levels of viral entry, transcription, and Gag assembly and processing. In this report, we describe an additional block in the selective packaging of tRNA(3Lys) into HIV-1 produced in murine cells. HIV-1 and murine leukemia virus (MuLV) use tRNA(3Lys) and tRNA(Pro), respectively, as primers for reverse transcription. Selective packaging of tRNA(3Lys) into HIV-1 produced in human cells is much stronger than that for tRNA(Pro) incorporation into MuLV produced in murine cells, and different packaging mechanisms are used. Thus, both lysyl-tRNA synthetase and GagPol are required for tRNA(3Lys) packaging into HIV-1, but neither prolyl-tRNA synthetase nor GagPol is required for tRNA(Pro) packaging into MuLV. In this report, we show that when HIV-1 is produced in murine cells, the virus switches from an HIV-1-like incorporation of tRNA(3Lys) to an MuLV-like packaging of tRNA(Pro). The primer binding site in viral RNA remains complementary to tRNA(3Lys), resulting in a significant decrease in reverse transcription and infectivity. Reduction in tRNA(3Lys) incorporation occurs even though both murine lysyl-tRNA synthetase and HIV-1 GagPol are packaged into the HIV-1 produced in murine cells. Nevertheless, the murine cell is able to support the select incorporation of tRNA(3Lys) into another retrovirus that uses tRNA(3Lys) as a primer, the mouse mammary tumor virus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842718      PMCID: PMC2593337          DOI: 10.1128/JVI.01744-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  A quantitative assay for HIV DNA integration in vivo.

Authors:  S L Butler; M S Hansen; F D Bushman
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.

Authors:  A Khorchid; H Javanbakht; S Wise; R Halwani; M A Parniak; M A Wainberg; L Kleiman
Journal:  J Mol Biol       Date:  2000-05-26       Impact factor: 5.469

3.  Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1.

Authors:  S Cen; A Khorchid; J Gabor; L Rong; M A Wainberg; L Kleiman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner.

Authors:  H Wodrich; A Schambach; H G Kräusslich
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

6.  Catalytic peptide of human glutaminyl-tRNA synthetase is essential for its assembly to the aminoacyl-tRNA synthetase complex.

Authors:  T Kim; S G Park; J E Kim; W Seol; Y G Ko; S Kim
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

7.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1.

Authors:  S Cen; A Khorchid; H Javanbakht; J Gabor; T Stello; K Shiba; K Musier-Forsyth; L Kleiman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  The connection domain in reverse transcriptase facilitates the in vivo annealing of tRNALys3 to HIV-1 genomic RNA.

Authors:  Shan Cen; Meijuan Niu; Lawrence Kleiman
Journal:  Retrovirology       Date:  2004-10-19       Impact factor: 4.602

View more
  3 in total

1.  Dual role for motif 1 residues of human lysyl-tRNA synthetase in dimerization and packaging into HIV-1.

Authors:  Varun Dewan; Min Wei; Lawrence Kleiman; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

2.  Initiation of HIV Reverse Transcription.

Authors:  Catherine Isel; Chantal Ehresmann; Roland Marquet
Journal:  Viruses       Date:  2010-01-18       Impact factor: 5.818

3.  Overexpressed coiled-coil domain containing protein 8 (CCDC8) mediates newly synthesized HIV-1 Gag lysosomal degradation.

Authors:  Xiangxiang Jiang; Xiaopeng Jia; Jinhuan Sun; Chunxia Qi; Lingling Lu; Yanfeng Wang; Lei Zhang; Min Wei
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.